Biotech Startups

Combat is a clinical-stage cancer treatment company focused on developing therapies for bladder and prostate cancer. The company is advised by leading urologic surgeons and oncologists specializing in robotic surgery and immunotherapy approaches.

2 investors

Commit Biologics develops a complement-targeted drug discovery platform and antibody-based therapeutics for oncology, autoimmune diseases, and infectious disease indications. The company combines structural biology and complement research to advance novel therapeutic programs.

2 investors

Complix develops therapeutic biologics based on Alphabody technology targeting viral diseases, oncology, and autoimmune conditions. The company focuses on cell-penetrating therapeutics designed to reach intracellular disease targets.

2 investors

Computomics develops AI and genomic foundation models for plant breeding, using machine learning on genetic, phenotypic, and environmental data to improve trait selection, prediction accuracy, and breeding cycle speed. It serves plant breeders and the agricultural sector working on resilient, high-yielding crops.

2 investors

Concentric AG produces microbial biological crop inputs that enhance plant vigor, soil health, and harvest yield while helping plants resist environmental stress and disease. The products are designed for growers in conventional agriculture and organic production, compatible with standard farming practices from field crops to greenhouse and hydroponic systems.

2 investors

Confluence Labs is an AI research lab developing models that improve learning efficiency, enabling faster scientific discovery with minimal experimental data. The company focuses on accelerating breakthroughs in drug and materials discovery by reducing the number of experiments needed to achieve results.

2 investors

Confluence Pharma is a clinical-stage biopharmaceutical company developing sustained-release drug formulations to treat the core social and communication impairments of Fragile X Syndrome, Autism, and other neurodevelopmental, neuropsychiatric, and addiction-related disorders. Its treatments target pediatric and adult patients, addressing symptoms such as communication, social behavior, attention, anxiety, and hyperactivity.

2 investors

Connect Biopharma is a clinical-stage biopharmaceutical company developing antibody-based therapies targeting inflammatory diseases such as atopic dermatitis and asthma. The company operates globally with headquarters in San Diego and operations in the U.S. and China.

2 investors

Conversio Health provides personalized therapeutics, technologies, and services for patients with chronic respiratory conditions and their caregivers. Founded in 2012, the company focuses on chronic respiratory care with the goal of improving outcomes and lowering costs.

2 investors

Convoke offers an AI platform that ingests and structures data from documents, scientific literature, SEC filings, and clinical data, and deploys custom agents to automate knowledge tasks and generate reports, manuscripts, and landscape analyses. It is built for biopharma teams working in competitive intelligence, medical affairs, portfolio strategy, and business development.

2 investors

Cordex Systems develops SmartCuff, a medical device that repurposes blood pressure cuff technology as a linear sensor to detect early warning signs of heart disease. The device is designed for healthcare professionals and patients at risk of cardiovascular disease.

2 investors

CORE Biomedicine is a biotech company developing precision cancer medicines based on cancer lineage biology, focused on advancing drug candidates from discovery into clinical development.

2 investors

CoreTissue BioEngineering develops a tissue-regenerating ligament implant for anterior cruciate ligament (ACL) reconstruction, using a proprietary decellularization technology to regenerate damaged tissue. The company aims to help athletes return to competition and recover peak performance, and is developing its medical device in Japan.

2 investors

CorrectSequence Therapeutics develops base-editing gene therapies using its proprietary transformer Base Editor (tBE) platform to treat genetic diseases, rare diseases, and common conditions including inherited disorders, metabolic diseases, cardiovascular diseases, and cancers. The company has advanced multiple pipeline candidates into clinical and investigational stages, including programs for β-thalassemia and sickle cell disease.

2 investors

Developer of a transcatheter InterAtrial Shunt Device to treat congestive heart failure.

2 investors

Cosaic develops ingredient solutions to create resilient food systems that align with consumer preferences. The company focuses on sustainability and industry resilience in food production.

2 investors

Cosomil develops single-molecule enzyme activity measurement technology for early disease diagnosis and drug development support in healthcare. The company serves medical research institutions, pharmaceutical manufacturers, and diagnostic laboratories in Japan.

2 investors

Cotton Mouton Diagnostics operates a UKAS-accredited laboratory offering endotoxin testing services for liquid pharmaceutical products, including method development, validation, and low endotoxin recovery studies. It also produces the αBET System, an in-house testing platform combining FUJIFILM Wako's licensed LAL reagent with its own magneto-optical technology for pharmaceutical and diagnostics customers.

2 investors

Cove builds brain data analytics tools that combine data engineering and neuroscience to support patient care. The company is developed by a team of physicians, neuroscientists, and software engineers.

2 investors

CREATE Medicines is a clinical-stage biotech company that develops in vivo mRNA immune cell programming therapies. The company focuses on RNA therapeutics and immune engineering for cancer, autoimmune disease, and transplant rejection applications.

2 investors

Lang Lai Technology (朗来科技) is a clinical-stage drug discovery company that runs an end-to-end new-drug R&D process spanning proof of concept, candidate compound screening, preclinical druggability development, and clinical research, pursuing both pipeline development and platform building. It operates R&D, translational medicine, and clinical centers across China and a business-development/FDA-filing center in the United States.

2 investors

Creoptix, a Malvern Panalytical brand, develops bioanalytical instruments for molecular interaction analysis, including its WAVE biosensor system for real-time kinetics and affinity studies of molecules such as small molecules, peptides, and proteins. Its tools serve drug discovery and life sciences research for both industry and academia.

2 investors

Creyon develops aptamer-delivered oligonucleotide therapeutics for targeted cell-specific delivery, including small interfering RNA and antisense oligonucleotides. The company's platform addresses limitations in tissue penetration and immunogenicity for central nervous system and other tissue-targeted applications.

2 investors

Cristal Therapeutics develops therapeutics in the life sciences sector. The page does not provide sufficient details about specific products, customer segments, or market focus to construct a fuller description.

2 investors